Sarepta Therapeutics (SRPT)

Sarepta Therapeutics Stock Price & Analysis


SRPT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$61.28 - $127.32
Previous Close$126.25
Average Volume (3M)1.09M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$2.07B
Total Debt (Recent Filing)$1.58B
Price to Earnings (P/E)-15.4
Next EarningsFeb 28, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-8.21
Shares Outstanding87,782,576
Standard Deviation0.17
10 Day Avg. Volume974,448
30 Day Avg. Volume1,085,944
Price to Book (P/B)25.06
Price to Sales (P/S)12.65
Price to Cash Flow (P/CF)54.10
P/FCF Ratio-37.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside13.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $61.28 and its highest was $127.32 in the past 12 months.
    What is Sarepta Therapeutics’s market cap?
    Currently, no data Available
    When is Sarepta Therapeutics’s upcoming earnings report date?
    Sarepta Therapeutics’s upcoming earnings report date is Feb 28, 2023 which is in 85 days.
      How were Sarepta Therapeutics’s earnings last quarter?
      Sarepta Therapeutics released its earnings results on Nov 02, 2022. The company reported -$2.94 earnings per share for the quarter, missing the consensus estimate of -$1.224 by -$1.716.
        Is Sarepta Therapeutics overvalued?
        According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Sarepta Therapeutics pay dividends?
          Sarepta Therapeutics does not currently pay dividends.
          What is Sarepta Therapeutics’s EPS estimate?
          Sarepta Therapeutics’s EPS estimate is -$1.43.
            How many shares outstanding does Sarepta Therapeutics have?
            Sarepta Therapeutics has 87,782,580 shares outstanding.
              What happened to Sarepta Therapeutics’s price movement after its last earnings report?
              Sarepta Therapeutics reported an EPS of -$2.94 in its last earnings report, missing expectations of -$1.224. Following the earnings report the stock price went down -7.415%.
                Which hedge fund is a major shareholder of Sarepta Therapeutics?
                Among the largest hedge funds holding Sarepta Therapeutics’s share is Sands Capital Management LLC. It holds Sarepta Therapeutics’s shares valued at 274M.


                  Sarepta Therapeutics Stock Smart Score

                  The Sarepta Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Sarepta Therapeutics

                  Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  BioMarin Pharmaceutical
                  United Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis